CTLA4 and colorectal carcinoma: For patients with pMMR-MSI-L colorectal cancer, combination therapy with PD1 inhibitors and other immune checkpoint molecular modulators (e.g., CTLA4) may benefit a small subset of patients with pMMR-MSI-L tumors, but for most patients with this CRC subtype, an alternative approach to immunomodulation is necessary.